Avoiding immune destruction is one emerging hallmark of cancer, including glioblastoma. The number of immunotherapy approaches to fight glioblastoma is growing. Here, we review the recent progress in four main areas: dendritic cell immunotherapy, peptide vaccination, chimeric antigen receptors and immune checkpoints.
INTRODUCTION
A growing amount of data led to consider immune escape as a novel hallmark of cancer [1 && ] and cancer immunotherapy as the scientific breakthrough of year 2013 [2] . These advances were mostly related to the treatment of melanoma and other solid tumors. Here, we review the ongoing preclinical and clinical progress in glioma immunotherapy in four main areas of research. Although data support novel hope, we believe that they should be considered critically and not overemphasized, to avoid future backlash that may weaken the field.
DENDRITIC CELL IMMUNOTHERAPY
Dendritic cells, discovered in 1973 by Steinman [3 && ], are devoted to acquire, process and present to T cells tumor antigens. Immunotherapeutic strategies exploit the ability of dendritic cells to drive T cells, B cells and natural killer (NK) cells to become potent antitumor effectors.
Anguille et al. [4 & ] summarized 2 decades of dendritic cell-based immunotherapy in different cancers including malignant gliomas. More than 500 malignant glioma patients were treated with dendritic cells and 15.6% showed an objective response. However, results were difficult to compare because of the lack of a standardized approach to dendritic cell preparation, treatment protocols, immunological follow-up and outcome evaluation [4 & ]. In another review of 21 clinical studies from 2000 to 2013 involving 403 glioblastoma patients, increased survival was associated to dendritic cell immunotherapy [5] .
Recently, we have analyzed survival and immunological parameters of the first 15 patients with recurrent glioblastoma whom we treated with mature dendritic cells loaded with whole, autologous tumor lysate [6 & ]. Increased frequency of NK cells in peripheral blood and functional activation through interferon (IFN)-g production correlated with increased progression-free survival (PFS) and overall survival (OS) of patients. Serum levels of transforming growth factor-b, vascular endothelial growth factor and interleukin-12 (IL-12) were also investigated, showing an inverse correlation of patient survival with immune suppressive immunological parameters and a positive correlation between increased PFS and IL-12 levels, which are associated to IFN-g production by NK cells. The maturation state of dendritic cells may have specifically favored dendritic cell and NK cell interaction and consequent potentiation of NK cell responses, as they may kill immature dendritic cells [7] .
An important confirmation of our observation comes from the recent comparison of two concurrent phase I studies using dendritic cells loaded with autologous tumor lysate or with synthetic gliomaassociated antigen peptides (GAA-dendritic cell) [8] . Dendritic cells loaded with tumor lysate did not undergo a maturation step. Dendritic cells loaded with GAA were administrated to the patients after a specific maturational step. Safety, feasibility and immune activation of patients enrolled in these trials were examined. In both, regulatory T lymphocyte (Treg) ratios decreased in patients with prolonged survival. On the contrary, increased frequencies of activated NK cells were observed in GAA-dendritic cell-treated patients, supporting the idea that dendritic cell maturation influences the immune response. Thus, even if dendritic cell vaccine parameters crucial for clinical effectiveness are not fully defined, it is now evident that mature rather than immature dendritic cells are more efficient in triggering immune responses and improve clinical outcome [4 & ]. Limited results have been obtained in pediatric patients affected by newly diagnosed or recurrent malignant gliomas treated with lysate-pulsed dendritic cells. Dendritic cell immunotherapy was tolerable and safe, but peripheral evaluation of cytokine levels showed some changes in relationship to dendritic cell vaccines in one patient only. Immunohistochemistry before and after immunotherapy of one anaplastic oligoastrocytoma failed to show immune cell infiltration [9] .
Two important constraints, outlined below, can limit the efficacy of dendritic cell immunotherapy 9] .
An immunosuppressive environment generated by the tumor or by immune suppressive components
Tregs and myeloid-derived suppressor cells are crucial in priming immunosuppression. Myeloidderived suppressor cells in particular can exert negative effect on NK cells and T cells and directly impair dendritic cell activity [4 & ,10]. Increasing evidence in many cancers supports the role of radiotherapy and chemotherapy in potentiating immune responses by modulating tumor microenvironment and exerting direct or indirect stimulatory effects on immune effector cells [11, 12] . Our observations on 22 patients with primary glioblastoma receiving standard radiotherapy and chemotherapy with temozolomide (TMZ) followed by adjuvant TMZ in combination with dendritic cell vaccines have shown increased systemic frequencies of natural killer T (NKT) cells and a vaccination or baseline ratios (postvaccination or prevaccination) significantly associated with prolonged PFS and OS [13] . The important role of NKT cells in potentiating a cancer-specific adaptive immune response [14 & ] encourages further investigation on these cells in antitumor response and on the potential of radiochemotherapy in their activation.
The capacity of escaping immune responses
Recent studies point to the role of cancer immunoediting as an important mechanism of tumor escape during immunotherapy [15] . Identifying novel targets essential for tumor perpetuation appears as one potential strategy to increase the efficacy of
KEY POINTS
Immunotherapy trials using dendritic cells loaded with whole glioblastoma lysate are ongoing and results on their efficacy will be available in the near future.
A phase III study based on vaccination with the EGFRvIII peptide is also ongoing. The EGFRvIII epitope is also targeted by CAR in a novel study.
Inhibitors of immune checkpoints (CTLA-4 and PD-1) have shown efficacy in advanced melanoma and are going to be tested in recurrent glioblastoma.
Advanced imaging techniques and immunological follow-up need to be tuned-up to improve predictions on tumor responses or progression and obtain meaningful results that may help the field to progress further.
glioblastoma immunotherapy and limit immune escape. Glioblastoma stem-like cells (GSCs) may represent a reproducible source of potential antigens truly at the core of tumor capacity for perpetuation that are otherwise 'diluted' in the tumor lysates [16 & ]. We are submitting to regulatory authorities a pilot study testing the safety and feasibility of GSCs as a novel target for dendritic cell immunotherapy in recurrent glioblastoma. A first evidence for safety and prolonged PFS of glioblastoma patients was reported in a clinical study on the basis of dendritic cells transfected with GSC mRNA [17] .
Several serious limitations slowed down the diffusion of dendritic cell immunotherapy, including the cost of clinical grade reagents and time-consuming procedures for dendritic cell manufacturing. Additionally, standard protocols for loading, differentiation and maturation of cells and common schemes for patient treatment are lacking. To overcome these limits, the use of artificial antigenpresenting cells has been proposed, to induce antigen-specific T cell activation both ex vivo and in vivo leading to efficient modulation of immune response and improved clinical responses [18, 19] .
PEPTIDE-BASED IMMUNOTHERAPY
Peptide immunotherapy exploits patient dendritic cells to elicit antitumor immune responses of clinical relevance. Vaccination against the epidermal growth factor receptor variant III (EGFRvIII) peptide is currently the reference point for this type of treatment. The peptide used in clinical trials (rindopepimut) matches the unique amino acid sequence that is consequent to the EGFR deletion of exons 2-6 occurring in 25% of the patients. Previous studies have demonstrated safety and evidence of immune response and have suggested a gain in PFS and OS vs. historically matched controls [20] . The ongoing phase III randomized CDX110-04 study (ACT IV protocol) will hopefully clarify whether the clinical advantage is significant.
In this and other immunotherapy trials, the definition of progression by MRI can be difficult, as immune reactions may be associated to contrast enhancement and T2 flair alterations (pseudoprogression). Advanced MRI may help in the definition of progression or pseudoprogression. Recent preclinical evidence of T cell detection in murine brain tumor studying intracellular oxygen by fluorine-19 MRI provides an interesting example of this potential [21 & ]. The use of bispecific single-chain antibodies (blinatumomab) redirecting T lymphocytes to CD19 (expressed on the earliest B-precursor lymphocytes that are malignantly transformed in acute lymphocytic leukemia) provided high rate of response and prolonged survival in patients with acute lymphoblastic leukemia that became refractory to chemotherapy [22] . Recently, evidence of activity for a similar bispecific T-cell engager antibody directed against the EGFRvIII epitope was found in a NOD/SCID gamma mice with established U87-EGFvIII brain tumors that were immune reconstituted with unstimulated human peripheral blood mononuclear cells [23] .
Interesting results have been recently achieved by peptide vaccination in pediatric gliomas [24 & ]. A number of trials failed to produce meaningful clinical advances for these tumors, in particular for diffuse intrinsic pontine gliomas (DIPGs) showing a median OS of 10 months [25] : this was recently exemplified by the negative results obtained with the EGFR antibody nimotuzumab [26] .
Pollack et al. [24 & ] performed vaccination in 26 children affected by high-grade gliomas or DIPG using peptide epitopes of three GAAs emulsified in montanide: ephrin A2 (EphA2), IL-13 receptor alpha 2 and survivin. Median survival was 12.7 months in 20 patients with DIPG and 25.1 in others with high grade gliomas. Patients who showed pseudoprogression at MRI survived 19.5 months (n ¼ 5), those without pseudoprogression 10.7 months. At IFN-g Enzyme-Linked ImmunoSpot, the majority of patients showed responses to IL-13 alpha 2 receptor or to EphA2, but not to survivin. Thus, vaccination with GAA peptides in children with gliomas was well tolerated and showed preliminary evidence of immunologic and clinical responses [24 & ]. As mentioned before, careful monitoring and management of pseudoprogression appeared of major importance.
Part of the previous data suggest that the selection of appropriate epitopes may impact on clinical results. We recently found that GLAST, a glutamate aspartate transporter expressed in radial glia, glioblastoma cells but also normal astrocytes, can be targeted in the GL261 model of glioblastoma [27] . Vaccination with four GLAST peptides was associated to the cure of 40% of the mice with established glioblastoma, in the absence of preliminary or concomitant radiotherapy or chemotherapy. Notably, we found no evidence for autoimmune reactions in these mice, even in organs in which GLAST is highly expressed, like cerebellum. It is plausible that the factors creating a local chemotactic gradient, which we found present at the tumor site, were able to restrict immune responses to the tumor. These included the tumor homing molecule very late antigen-4, CXCL10 [facilitating the recruitment of cytotoxic T cells], CCL3, CCL4 and CCL5, involved in NK-cell migration and the NKG2D ligand on glioma cells [27] .
Another important target that we found 'actionable' by immunotherapy is the (cancer) stem cell gene SOX2 [Sex-determining region Y (SRY)-Box2]. SOX2 expression was found critical for tumorigenesis in the oligodendroglioma model we studied [28 & ], but also in glioblastoma [29] and other more frequent tumors, like squamous cell carcinomas [30] . In these latter cases, SOX2 was necessary to govern a main feature of cancer adaptation to the environment, cancer stem-like cell plasticity, that is, the capacity to revert from a partially differentiated to a stem-like status. We found that peptide vaccination against SOX2 significantly prolonged survival in mice and was additive but not synergic with concurrent administration of TMZ [28 & ]. An important and puzzling feature of these experiments was the demonstration that an immune reaction could target a transcription factor usually located in the nucleus.
Finally, very recent data indicate that isocitrate dehydrogenase 1 (IDH1) mutations are also immunologically targetable [31 & ]. IDH1 mutations are frequent in lower grade gliomas, present in 8-10% of glioblastomas and in other cancers [32] . They mostly affect the catalytic pocket of this cytoplasmic form of the enzyme at arginine residue 132 [32] . Vaccination with peptides encompassing the mutation in A2.DR1 mice transgenic for human major histocompatibility complex (MHC) class I and II [33] caused MHC class II-restricted, mutationspecific antitumor immune responses and control of preestablished tumors that was based on CD4þ T-cells. Tumors treated by vaccination were sarcomas obtained by subcutaneous administration of 3-methylcolantrene to A2.DR1 mice, subsequently transduced with retroviral vectors carrying the R132H mutation. However, the translational relevance of the model was enhanced by humanized MHC restriction of IDH1 mutated peptides without competition of mouse MHC [31 & ].
CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
An antigen-specific cytotoxic T cell can recognize tumor cells if they express antigens in the context of MHC class I. This is a real conundrum in case of tumors with alterations in genetic programs associated with the antigen processing and presentation machinery. To circumvent this problem, T cells that do not require antigen presentation in the MHC class I context have been built. These 'supernatural' T cells engineered to possess chimeric antigen receptors (CARs) represent one such tool [34 & ]. T cells with CARs express a fusion protein that consists of a specific single-chain variable fragment on the extracellular domain, a cytosolic signaling domain CD3 chain and a costimulatory molecule (CD28 and 4-1BB). This approach combines the effector functions of T cells with the ability of antibodies to recognize predefined surface antigens with high specificity and avidity, independent of MHC restriction.
CAR therapies are being tested in patients with a variety of cancers. The experience of CARs in glioblastoma is limited; however, recent clinical results using CAR T cells to treat diverse cancers expressing an epitope of L1 cell adhesion molecule [35] and CD19-positive leukemia [36] encourage further explorations.
In-vitro data showed that EphA2-specific CAR T cells recognized EphA2-positive glioma cells and GSCs in vitro, as evaluated by IFN-g secretion, and induced tumor regression in glioblastoma xenografts. More recently, it has been shown that SMA560vIII (EGFRvIII pos glioma)-bearing immune competent mice were cured by systemic infusions of elevated doses of a third generation EGFRvIIIspecific murine CAR. Unexpectedly, these mice developed long-lasting immune responses against EGFRvIII neg tumors, supporting the ability of this approach to contribute to the development of host immunity against tumor-antigen escape compared with the peptide vaccine approach whose efficacy has been limited by immunoediting [37 & ]. Subsequently, intracranial delivery of third generation EGFRvIII-specific CAR was used to treat EGRvIII pos tumors in NOD SCID gamma mice demonstrating the safety and specificity of this approach [38] .
CAR-modified T cells constitute an appealing therapeutic approach because of their ability to circumvent many barriers inherent to tumor microenvironment and optimize T-cell specificity, activation, homing and antitumor function. Disadvantages include technical challenges related to the clinical use of genetically engineered T cells, and the risk (both real and perceived) of unexpected on-target or off-target effects. In order to avoid severe adverse reactions, a careful selection of targetable tumor-specific antigens is crucial to improve efficacy and safety of CAR T cell therapy [39] . Additional factors to be considered include the costimulatory signals, which may contribute to severe side-effects like the 'cytokine storm' and T cell repression [40] .
Future collective efforts will be required to improve the quality of engineered T cells that depends on many factors including standardized activation and expansion methods, selection of T cell subsets with therapeutic potential, etc. The development of comprehensive approaches is necessary to maximize efficacy of this immunotherapeutic strategy.
IMMUNE CHECKPOINTS
These membrane proteins are important to maintain immune homeostasis, exercising a negative control on the amplification of T-cell-mediated immune responses. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is expressed on T cells in which it controls the amplitude of early T cell activation by counteracting the activity of the T cell costimulatory receptor, CD28 [41 && ]. A strong evidence of CTLA-4 role was found in knock-out mice that developed multiorgan attacks by T cell blasts that were lethal in 3 to 4 weeks after birth [42] . A phase III study on 676 patients with metastatic melanoma compared treatment with the anti-CTLA-4 antibody ipilimumab 3 mg/kg with or without the glycoprotein 100 (gp100) vaccine and gp100 alone. OS of patients treated with ipilimumab and gp100 was 10.0 months and 6.4 months in patients treated with gp100 only (P < 0.001) [43 && ]. Another phase III randomized study compared survival in previously untreated melanoma treated with ipilimumab 10 mg/kg plus dacarbazine or dacarbazine plus placebo [44] . OS was 11.2 vs. 9.1 months, respectively. Grade 3 to 4 adverse events occurred in 56.3% of patients treated with 10 mg/kg ipilimumab and in 10-15% of patients treated with 3 mg/kg ipilimumab in the study on metastatic melanomas [43 && ,44] .
Two randomized phase II studies tested ipilimumab in combination with paclitaxel and carboplatin in patients with nonsmall cell lung cancer or small cell lung cancer, respectively [45, 46] . In both cases phased (i.e., given after chemotherapy) rather than concurrent ipilimumab showed some advantage in terms of immune-related PFS [47] .
Programmed cell death-1 (PD-1) is the other emerging immune checkpoint [41 && ]. PD-1 encounters its ligands PD-L1 and/or PD-L2 in peripheral tissues in which it controls T cell activity to avoid autoimmunity. The anti-PD-1 antibody nivolumab was used in conjunction with ipilimumab in a phase I study in advanced melanoma [48 & ]. Evidence of clinical activity at different levels was found in 65% of the patients but grade 3 to 4 adverse events occurred in 53% of the cases [48 & ]. Clinical advantage from nivolumab in 107 patients with advanced melanoma was confirmed in another study: 1-year and 2-year survival rates were 62 and 43%, respectively [49] . Another anti-PD-1 antibody, lambrolizumab, was used in a pilot study in 135 patients with advanced melanoma. Most of the adverse events were low grade. The response rate was 38% and did not differ significantly between patients who received or did not receive prior ipilimumab treatment. The median PFS was longer than 7 months [50 & ]. At present, the experience with immune checkpoints in gliomas is only preclinical. IL-12 application in established GL261 tumors combined with systemic blockade of CTLA-4 led to tumor eradication whereas monotherapy with either IL-12 or CTLA-4 blockade failed. The treatment caused a remarkable decrease in forkhead box p3 (Foxp3)þ Tregs and an increase in effector T cells [51] . In the same experimental model, another study demonstrated that inhibition of IDO, CTLA-4 and PD-L1 decreases tumor-infiltrating Tregs, in association to T cell-mediated long-term survival [52] . Again in the GL261 model, improved survival was demonstrated by combined anti-PD-1 therapy plus radiation compared with either modality alone. Also, in this setting, increased tumor infiltration by cytotoxic T cells and decreased Tregs was detected in the combined treatment group [53] .
Overall, the clinical results registered in melanomas and the preclinical data create expectations for the imminent start of randomized studies with single or combined targeting of immune checkpoints in glioblastoma patients.
CONCLUSION
The data we have reviewed provide the picture of a dynamic field, glioma immunotherapy, that entered the clinical arena creating considerable expectations. Phase III trial of EGFRvIII immunotherapy and phase II trials based on dendritic cell immunotherapy are ongoing and will likely produce results in the near future. Clinical studies involving the use of CAR just started, and clinical testing of immune checkpoint inhibitors in gliomas is imminent. The combination of target specificity, provided by the first three approaches, with the unspecific amplification intrinsic to checkpoint inhibition, has the potential to be synergic. However, with increasing signs of efficacy we now start to see signs of immune toxicity as well as MRI features that make it difficult to differentiate true from pseudo-progression. Dealing properly with these issues will be important to avoid premature termination of potentially promising studies.
